TARRYTOWN, NY, Oct. 10, 2023 (GLOBE NEWSWIRE) -- via Globe newswire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced its Gold Sponsorship of The BRAIN Foundation's esteemed Synchrony Symposia 2023.

The Synchrony Symposia is a globally recognized event that serves as a catalyst for translational research in autism and related neurodevelopmental disorders. This symposium brings together leading scientists, clinicians, biotech and pharmaceutical companies, venture partners, and community stakeholders to foster scientific advancements that can enhance the well-being and quality of life for individuals affected by ASD.

PaxMedica's commitment to this critical cause aligns seamlessly with the symposium's mission to promote collaboration, innovation, and the dissemination of innovative research in the field of neurodevelopmental disorders. As the only publicly traded U.S. company exclusively primarily focused on autism, PaxMedica is dedicated to developing groundbreaking therapies that address the unmet medical needs of individuals with ASD.

"We are honored to support The BRAIN Foundation's Synchrony Symposia. This symposium plays a pivotal role in advancing scientific knowledge and fostering collaboration among experts in the field of autism research. PaxMedica is deeply committed to improving the lives of individuals with autism and their families, and we are excited to contribute to this vital initiative," stated Howard Weisman, Chairman and CEO of PaxMedica.

The symposium offers a platform for attendees to engage in interdisciplinary discussions, gain insights from leading experts, and participate in research presentations, clinical roundtables, mentor-mentee sessions, and more. Through its Gold Sponsorship, PaxMedica demonstrates its unwavering dedication to supporting research that can lead to meaningful advancements in the understanding and treatment of neurodevelopmental disorders.

‍

About PaxMedica

PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder. One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancing the clinical understanding of using that agent against other disorders such as ME/CFS. For more information, visit www.paxmedica.com .

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at www.paxmedica.com/email-alerts and by following PaxMedica  on Twitter, YouTubeand LinkedIn

‍

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. These forward-looking statements include our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory filings, statements about the strength of our balance sheet. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn and risks associated with intellectual property and infringement claims.  The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s “Risk Factors” section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission.